Drug details

Takhzyro (lanadelumab-flyo injection)

type of Kallikrein Inhibitors

Takhzyro (lanadelumab-flyo) is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• lightheadedness
• swelling of your face, lips, tongue, or throat, and

The following drugs are related to Takhzyro, either as a replacement or used together:

• Berinert ([c1 esterase inhibitor (human)] freeze-dried powder)
• Orladeyo (berotralstat capsules)
• Cinryze (c1 esterase inhibitor [human] freeze dried powder)
• Ruconest (c1 esterase inhibitor [recombinant] intravenous injection)
• Haegarda (c1 esterase inhibitor subcutaneous [human] injection)
• Kalbitor (ecallantide injection)
• Firazyr (icatibant injection for subcutaneous administration)
• Sajazir (icatibant injection, for subcutaneous use)